Duska Therapeutics, Inc.

Company, U of Pennsylvania ink agreement for ATPotent preclinical studies

Published in Pharma Investments, Ventures and Law Weekly, July 17th, 2005

Duska Therapeutics, Inc., (DSKT) has entered into an agreement with the University of Pennsylvania (Penn) under which preclinical studies with ATPotent will be carried out at Penn's Center for Research on Reproduction and Women's Health.

ATPotent, which is a liquid formulation of adenosine 5'-triphosphate (ATP), is being developed by Duska as a proprietary drug for the treatment of male infertility in conjunction with intrauterine insemination and in vitro fertilization.

There are approximately 6 million infertile couples seeking medical help annually in the U.S.; the male factor is at least partly responsible for the infertility in about 50% of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly

Source: Pharma Investments, Ventures and Law Weekly (2005-07-17)

More Articles from Pharma Investments, Ventures and Law Weekly

Arrowhead Research Corporation
Nanotech company revises commercialization strategy
Arrowhead Research Corporation
Nanotechnology firm completes warrant redemption
BioVeris Corporation
Diagnostics company reports loss of $0.27 per share
Biophan Technologies, Inc.
Patent allowed for solution to enhance image quality of MRI
CV Therapeutics, Inc.
Biopharmaceutical firm reports option grants
Caraco Pharmaceutical Laboratories, Ltd.
Pharmaceutical company reports 27% increase in sales
More from this issue of Pharma Investments, Ventures and Law Weekly

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry